Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data

References

• Albert DA. Are all biologics the same? Optimal treatment strategies for patients with early rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. J Clin Rheumatol. 2015;21:398–404.
   PubMed Web of Science ®Google Scholar
• Alfonso-Cristancho R, Armstrong N, Arjunji R, Riemsma R, Worthy G, Ganguly R, et al. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clin Rheumatol. 2017;36:25–34.
   PubMed Web of Science ®Google Scholar
• Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, et al. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Curr Med Res Opin. 2006;22:169–83.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther. 2011;13:R155.
   PubMed Web of Science ®Google Scholar
• Ochiai M, Sato E, Tanaka E, Inoue E, Nakajima A, Momohara S, et al. Discontinuation of biologics in patients with rheumatoid arthritis after achieving low-activity disease status. Arthritis Rheumatol. 2014;66(10):S213.
   Google Scholar
• Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol. 2013;42:253–9.
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Kondo M, Fukuda T, Harada H, Horiuchi T, Ishinishi T, et al. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data. Mod Rheumatol. 2014;24:258–64.
   PubMed Web of Science ®Google Scholar
• Notario F, Ferrer G, Morales G, González U, García S, Soto P, et al. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice. Reumatol Clin. 2017;13:78–84. [Article in English, Spanish]
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Goto H, Hirano K, Nakajima A, Origasa H, Tanaka K, et al. Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol. 2015;42:1368–75.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res (Hoboken). 2016;68:432–9.
   PubMed Web of Science ®Google Scholar
• Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, et al. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine. 2014;81:352–9.
   PubMed Web of Science ®Google Scholar
• Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L. Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics. 2015;9:119–27.
   PubMedGoogle Scholar
• Hirabara S, Takahashi N, Fukaya N, Miyake H, Yabe Y, Kaneko A, et al. Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol. 2014;33:1247–54.
   PubMed Web of Science ®Google Scholar
• Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, et al. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Mod Rheumatol. 2015;25:251–6.
   PubMed Web of Science ®Google Scholar
• Baser O, Ganguli A, Roy S, Xie L, Cifaldi M. Impact of switching from an initial tumor necrosis factor inhibitor on health care resource utilization and costs among patients with rheumatoid arthritis. Clin Ther. 2015;37:1454–65.
   PubMed Web of Science ®Google Scholar
• Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, et al. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52. Mod Rheumatol. 2015;25:31–7.
   PubMed Web of Science ®Google Scholar
• Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, et al. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis. 2016;75:1336–42.
   PubMed Web of Science ®Google Scholar
• Matsubara H, Kojima T, Kaneko A, Hirano Y, Ishikawa H, Hattori Y, et al. Long term retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy. J Rheumatol. 2014;41:1583–9.
   Web of Science ®Google Scholar
• Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, et al. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2015;67:624–32.
   PubMed Web of Science ®Google Scholar
• Matsuno H, Katayama K. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab. Mod Rheumatol. 2017;27:246–51.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Kaneko Y, Kondo H, Takeuchi T. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. Clin Rheumatol. 2016;35:2829–34.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Symmons DP, Watson KD, Silman AJ. British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:1786–94.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856–62.
   PubMed Web of Science ®Google Scholar
• Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Mölken MP, Liao KP, et al. Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. Rheumatology (Oxford). 2016;55:809–16.
   PubMed Web of Science ®Google Scholar
• Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR. Comparative persistence of the TNF antagonists in rheumatoid arthritis – a population-based cohort study. PLoS One. 2014;9:e105193.
   PubMed Web of Science ®Google Scholar
• Cox ER, Motheral B, Mager D. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s). Am J Manag Care. 2003;9:785–94.
   PubMed Web of Science ®Google Scholar
• Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol. 2009;36:907–13.
   PubMed Web of Science ®Google Scholar
• Neubauer S, Cifaldi M, Mittendorf T, Ganguli A, Wolff M, Zeidler J. Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Econ Rev. 2014;4:32.
   PubMedGoogle Scholar
• Bonafede MM, Gandra SR, Fox KM, Wilson KL. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ. 2012;15:635–43.
   PubMedGoogle Scholar
• Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. JMCP. 2013;19:621–30.
   PubMed Web of Science ®Google Scholar
• Sugiyama N, Kawahito Y, Fujii T, Atsumi T, Murata T, Morishima Y, et al. Treatment patterns, direct cost of biologics, and direct medical costs for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data. Clin Ther. 2016;38:1359–75.
   PubMed Web of Science ®Google Scholar
• Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995;9:619–32.
   PubMed Web of Science ®Google Scholar
• Krack G, Zeidler H, Zeidler J. Claims data analysis of tumor necrosis factor inhibitor treatment dosing among patients with rheumatoid arthritis: a systematic review of methods. Drugs Real World Outcomes. 2016;3:265–78.
   PubMedGoogle Scholar
• Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, et al. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis. JMCP. 2014;20:657–67.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41:15–23.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma I, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:343–51.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese post-marketing surveillance study. Rheumatol Int. 2012;32:1617–24.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24:390–8.
   PubMed Web of Science ®Google Scholar
• Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2016;26:491–8.
   PubMed Web of Science ®Google Scholar
• Kanbori M, Suzuka H, Yajima T, Kishino E, Morishige R, Momohara S, et al. Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2018;28:66–75.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Mod Rheumatol. 2016;26:473–80.
   PubMed Web of Science ®Google Scholar
• Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol. 2016;68:56–66.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843–7.
   PubMed Web of Science ®Google Scholar
• Hudson M, Tascilar K, Suissa S. Comparative effectiveness research with administrative health data in rheumatoid arthritis. Nat Rev Rheumatol. 2016;12:358–66.
   PubMed Web of Science ®Google Scholar
• Yun H, Curtis JR. New methods for determining comparative effectiveness in rheumatoid arthritis. Curr Opin Rheumatol. 2013;25:325–33.
   PubMed Web of Science ®Google Scholar